- Home
- OIM vs GLSI Comparison
OIM vs GLSI Comparison
Compare OIM & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OIM | GLSI |
|---|---|---|
| Founded | 2025 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.4M | 372.0M |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OIM | GLSI |
|---|---|---|
| Price | $10.04 | $21.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 80.5K | ★ 112.6K |
| Earning Date | N/A | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.96 | $7.78 |
| 52 Week High | $10.10 | $34.10 |
Technical Indicators
Market Signals| Indicator | OIM | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 58.45 | 40.51 |
| Support Level | $9.96 | $21.20 |
| Resistance Level | $10.10 | $30.08 |
| Average True Range (ATR) | 0.02 | 1.99 |
| MACD | 0.00 | -0.32 |
| Stochastic Oscillator | 57.14 | 3.22 |
Price Performance
Historical ComparisonAbout OIM OneIM Acquisition Corp. Class A Ordinary Shares
OneIM Acquisition Corp is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.